Atara announces FDA agreement on tab-cel comparability; BLA submission planned Q2 2024

Atara Biotherapeutics, Inc.

FDA and Atara aligned on analytical comparability between manufacturing process versions of tab-cel.
Alignment allows pooling of pivotal clinical trial data from different process versions for BLA.
Atara expects to submit tab-cel BLA in Q2 2024, enabling inclusion of Phase 3 ALLELE data.
Company also advancing U.S. partnership discussions for tab-cel commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.